Media & Resources

In two recent publications, IAVI authors point to the need for an expanded global commitment to HIV vaccine development and suggest a suite of regulatory, policy, and implementation activities to ensure access to new HIV prevention tools.

Research published in Science could be applied beyond HIV to other diseases.

Website update includes stage gates for registration and launch, guidance for specific vaccine categories.

Ayesha Sitlani describes an approach to making antibody-based preventives and treatments globally accessible.

IAVI recognizes the Norwegian government and its Norwegian Development Agency (Norad) for its continued commitment to HIV vaccine research and applauds its dedication to global health research and development.

IAVI recognizes USAID and the American people for their unwavering support of the development of safe, effective, accessible, preventive HIV vaccines and biomedical prevention products for use throughout the world.

First-in-human clinical trial results of IAVI A003 study published in The Lancet HIV.

World TB Day falls on March 24 each year. It marks the day in 1882 when Robert Koch announced that he had identified the cause of TB.